Advertisement

Klinik und Therapie der Helicobacter-pylori-Infektion

  • W. Opferkuch
  • M. Kist
  • W. F. Caspary

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Adamek RJ, Suerbaum S, Pfaffenbach B, Opferkuch W (1998) Primary and aquired Helicobacter pylori resistance to clarithromycin, metronidazole and amoxicillin. Am J Gastroenterol 93: 386–389PubMedGoogle Scholar
  2. Adamsson I, Edlund C, Nord CE (2000) Microbial ecology and treatment of Helicobacter pylori infection: Rev J Chemother 12: 5–16Google Scholar
  3. Andersen IP, Colding H, Kristiansen JE (2000) Potentiation of the action of metronidazole on Helicobacter pylori by omeprazol and Bismuth subcitrate. Int J Antimicrob Agents 14: 231–234PubMedCrossRefGoogle Scholar
  4. Bayerdörffer E, Hansky K, Schneider-Brachert W et al. (2002) Treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin — a prospective randomized trial comparing a 7-day rifabutin-based triple therapy with a high dose omeprazole/amoxiillin dual therapy. Gut 51(Suppl II): A91Google Scholar
  5. Bereswill S, Krainick C, Stahler F, Herrmann L, Kist M. (2003) Analysis of the rdxA gene in high-level metronidazole-resistant clinical isolates confirms a limited use of rdxA mutations as a marker for prediction of metronidazole resistance in Helicobacter pylori FEMS. Immunol Med Microbiol 36: 193–198CrossRefGoogle Scholar
  6. Best LM, Haldane DJ, Keelan M et al. (2003) Multilaboratory comparison of proficiencies in susceptibility testing of Helicobacter pylori and correlation between agar dilution and E test methods. Antimicrob Agents Chemother 47: 3138–3144PubMedCrossRefGoogle Scholar
  7. Blandizzi C, Malizia T, Gherardi G et al. (1998) Gastric mucosal distribution and clinical efficacy of azithromycin in patients with Helicobacter pylori related gastritis. J. Antimicrob Chemother 42: 75–82PubMedCrossRefGoogle Scholar
  8. Calabrese C, Di Febo G, Areni A, Scialpi C, Biasco G, Miglioli M (2000) Pantoprazole, azithromycin and tinidazole: short duration tripletherapy for eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 14: 1613–1617PubMedCrossRefGoogle Scholar
  9. Cammarota G, Papa A, Cianci R et al. (1999) Three-day antibiotic therapy with azithromycin and tinidazole plus lanzoprazole or pantoprazole to cure Helicobacter pylori infection: a pilot study. Eur J Gastroenterol Hepatol 11: 247–250PubMedGoogle Scholar
  10. Caspary WF, Arnold R, Bayerdörffer E et al. (1996) Diagnostik und Therapie der Helicobacter pylori Infektion. Leitlinien der DGVS. Z Gastroenterologie 34: 392–401Google Scholar
  11. Cooreman MP, Krausgrill P, Hengels KJ (1993) Local gastric and serum Amoxicillin concentrations after different oral application forms. Antimicrob Agents Chemother 37: 1506–1509PubMedGoogle Scholar
  12. de Boer WA (1999) Bismuth triple therapy is still a very important drug regime for curing Helicobacter pylori infection. Eur J Gastroenterol Hepatolol 11: 697–700Google Scholar
  13. DeCross AJ, Marshall BJ, McCallum RW et al. (1993) Susceptibility testing for Helicobacter pylori: comparison of disk, broth, and agar dilution methods and their clinical relevance. J Clin Microbiol 31: 1971–1974PubMedGoogle Scholar
  14. De Martel C, Llosa AE, Farr SF et al. (2005) Helicobacter pylori infection and the risk of development of esophageal adenocarcinoma. J Infect Dis 191: 761–767PubMedCrossRefGoogle Scholar
  15. Dooley CP, Cohen H, Fitzgibbons P et al. (1989) Prevalence of Helicobacter pylori and histologic gastritis in asymptomatic persons. N Engl J Med 321: 1562–1566PubMedCrossRefGoogle Scholar
  16. Dore MP, Leandro G, Realdi G, Sepulveda AR, Graham DY (2000) Effect of pretreatment antibiotic resistance to Metronidazole and Clarithromycin on outcome of Helicobacter pylori therapy: A Meta-Analytical approach. Dig Dis Sci 45: 68–76PubMedCrossRefGoogle Scholar
  17. Dore MP, Piana A, Carta M et al. (1998) Amoxicillin resistance is one reason for failure of Amoxicillin-Omeprazole treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 12: 635–639PubMedCrossRefGoogle Scholar
  18. Erah PO, Goddard AF, Barrett DA, Shaw PN, Spiller RC (1995) Effect of pH on the stability of Amoxicillin in buffered aqueous solution and in gastric juice. Pharm Sci 1: 597–600Google Scholar
  19. Ferrero M., Ducons JA, Santolaria B, Sierra E, Gomollon F (2000). Factors affecting the variation in antibiotic resistance of Helicobacter pylori. Int J Antimicrob Agents 16: 245–248.PubMedCrossRefGoogle Scholar
  20. Fischbach W (2005) Tumore des Magens. In: Caspary WF, Mössner J, Stein J (Hrsg) Therapie gastroenterologischer Krankheiten. Springer, Heidelberg Berlin New York, S 90–97Google Scholar
  21. Fraser AG, Moore L, Hackett M, Hollis B (1999). Helicobacter pylori treatment and antibiotic susceptibility: Result of a fife-year Audit. Aust N Z J Med 29: 512–516PubMedGoogle Scholar
  22. Furuta T, Ohashi K, Kamata T et al. (1998) Effect of genetic differences in omeprazole metabolism on cure rate of Helicobacter pylori infection and peptic ulcer. Ann Intern Med 129: 1027–1030PubMedGoogle Scholar
  23. Gerloff J, Mignot A, Barth H et al. (1996) Pharmacokinetics and absolute bioavailability of Lanzoprazole. Eur J Clin Pharmacol 50: 293–297PubMedCrossRefGoogle Scholar
  24. Gisbert JP, Boixeda D, Bermojo F et al. (1999) Re-treatment after Helicobacter pylori eradication failure. Eur J Gastroenterol Hepatol 11: 1049–1054PubMedCrossRefGoogle Scholar
  25. Gisbert JP, Calet X, Bujanda I, Marcos S, Gisbert JL, Pajares JM (2003) ‘Rescue’ therapy with rifabutin after multiple Helicobacter pylori treatment failures. Helicobacter 88: 90–94CrossRefGoogle Scholar
  26. Goddard AF (1998) Review Article: Factors influencing antibiotic transfer across the gastric mucosa. Aliment Pharmacol Ther 12: 1175–1184PubMedCrossRefGoogle Scholar
  27. Goddard AF, Jessa MJ, Barrett DA et al. (1996). Effect of Omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice. Gastroenterology 111: 358–367PubMedCrossRefGoogle Scholar
  28. Greenberg RE, Bank S (1990) The prevalence of Helicobacter pylori in nonulcer dyspepsia. Arch Intern Med 150: 2053–2055PubMedCrossRefGoogle Scholar
  29. Gschossmann JM, Haag S, Holtmann G (2001) Epidemiological trends of functional gastrointestinal disorders. Dig Dis 19: 189–194PubMedCrossRefGoogle Scholar
  30. Harrison JD, Jones JA, Morris DL (1991) Azithromycin levels in plasma and gastric tissue, juice and mucus. Eur J Clin Microbiol Infect Dis 10: 862–864PubMedCrossRefGoogle Scholar
  31. Heep M, Beck D, Bayerdörffer E, Lehn N (1999) Rifampin and Rifabutin resistance mechanism in Helicobacter pylori. Antimicrob Agents Chemother 43: 1497–1499PubMedGoogle Scholar
  32. Helicobacter and Cancer Collaborative Group (2001) Gastric cancer and Helicobacter: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 49: 247–353CrossRefGoogle Scholar
  33. Hirschl AM, Hirschl MM, Rotter ML (1993) Comparison of three methods for the determination of the sensitivity of Helicobacter pylori to metronidazole. J Antimicrob Chemother 32: 45–49PubMedGoogle Scholar
  34. Holtmann G, Goebell H, Holtmann M, Talley NJ (1994) Dyspepsia in healthy blood donors: Pattern of symptoms and association with Helicobacter pylori. Dig Dis Sci 39: 1090–1098PubMedCrossRefGoogle Scholar
  35. Horn J (2000) The proton-pump inhibitors: Similarities und differences. Clin Ther 22: 266–280PubMedCrossRefGoogle Scholar
  36. Houben MHMG, van de Beek D, Hensen EF, De Craen AKM, Rauws EAJ (1999) A systematic review of Helicobacter pylori eradication therapy — The impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther 13: 1047–1055PubMedCrossRefGoogle Scholar
  37. Huang JQ, Sridhar S, Chen Y, Hunt RH (1998) Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 114: 1169–1179PubMedCrossRefGoogle Scholar
  38. Huang JQ, Zheng GF, Sumanac K, Irvine EJ, Hunt RH (2003) Meta-analysis of the relationship between cagA seropositivity and gastric cancer. Gastroenterology 125: 1636–1644PubMedCrossRefGoogle Scholar
  39. Huber R, Hartmann M, Biesath H et al. (1996) Pharmacokinetics of Pantoprazole in man. Int J Pharmacol Ther 34(Suppl 1): S31–S50Google Scholar
  40. Jeong J-Y, Mukhopadhyay AK, Dailidiene D et al. (2000) Sequential inactivation of rdxA (HP0954) and frxA (HP0642) nitroreductase genes causes moderate and high-level Metronidazole resistance in Helicobacter pylori. J Bacteriology 18: 5082–5090CrossRefGoogle Scholar
  41. Jungnickel PW (2000) Pantoprazole: A new proton-pump inhibitor. Clin Ther 22: 1268–1293PubMedCrossRefGoogle Scholar
  42. Kalach N, Bergeret M, Benhamou PH, Dupont C, Raymond J (2001) High levels of resistance to metronidazole and clarithromycin in Helicobacter pylori strains in children. J Clin Microbiol 39: 394–397PubMedCrossRefGoogle Scholar
  43. Kist M, Berreswill S (1997) Helicobacter pylori. Teil 2: Epidemiologie, Diagnose und Therapie. Mikrobiologe 7: 209–211Google Scholar
  44. Klotz U (2000) Pharmacokinetic considerations in the eradication of Helicobacter pylori. Clin Pharmacokinet 38: 243–270PubMedCrossRefGoogle Scholar
  45. Labenz J, Börsch G (2000) Therapie der Helicobacter pylori Infektion. In: Malfertheiner P (Hrsg) Helicobacter pylori — Von der Grundlage zur Therapie. Thieme, Stuttgart, S 157–172Google Scholar
  46. Laine L, Schoenfeld P, Fennerty MB (2001) Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials. Ann Intern Med 134(5): 361–369PubMedGoogle Scholar
  47. Lind T, Mégraud F, Unge P et al. (1999) The MACH 2 Study: Role of Omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 116: 248–253PubMedCrossRefGoogle Scholar
  48. Lind T, Veldhuyzen S, Unge P et al. (1996) Eradication of Helicobacter pylori using one-week tripple therapy combining omeprazole with two antimicrobials: the MACH 1 study. Helicobacter 1: 138–144PubMedGoogle Scholar
  49. Lozniewski A, de Korwin JD, Muhale F, Jehl F (1998) Gastric diffusion of antibiotics used against Helicobacter pylori. Int J Antimicrob Agents 9: 181–193CrossRefGoogle Scholar
  50. Malfertheiner P, Holtmann G, Peitz U et al. (2001) Leitlinien der Deutschen Gesellschaft für Verdauungs-und Stoffwechselerkrankungen zur Behandlung der Dyspepsie. Z Gastroenterol 39(11): 937PubMedCrossRefGoogle Scholar
  51. Malfertheiner P, Mégraud F, O’Morain C et al. (2002). Current concepts in the management of Helicobacter pylori infection — the Maastricht 2–2000 Consensus Report. Aliment Pharmacol Ther 16: 167–180PubMedCrossRefGoogle Scholar
  52. Manes G, Dominguez-Munoz JE, Uomo G et al. (1998) Increased risk for Helicobacter pylori recurrence by continuous acid suppression: a randomized controlled study. Ital J Gastroenterol Hepatol 30: 28–33PubMedGoogle Scholar
  53. Mégraud F, Lehn N, Lind T et al. (1999) Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2-Study. Antimicrob Agents Chemother 43: 2747–2752PubMedGoogle Scholar
  54. Mendz GL, Mégraud F (2002) Is the molecular basis of metronidazole resistance in microaerophilic organisms understood? Trends Microbiol 10: 370–375PubMedCrossRefGoogle Scholar
  55. Midolo P, Turnidge JD, Lambert JR (1997) Bactericidal activity and synergy studies of proton pump-inhibitors and antibiotics against Helicobacter pylori in vitro. J Antimicrob Chemother 39: 331–337PubMedCrossRefGoogle Scholar
  56. Mirshahi F, Fowler G, Patel A, Shaw G (1998). Omeprazole may exert both a bacteriostatic and a bactericidal effect on the growth of Helicobacter pylori (NCTC11637) in vitro by inhibiting bacterial urease activity. J Clin Pathol 51: 220–224PubMedCrossRefGoogle Scholar
  57. Ohkusa T, Fujiki K, Takashimizu I et al. (2001) Improvment in atrophic gastritis an intestinal metaplasia in patients in whom Helicobacter pylori was eradicated. Ann Intern Med 134: 380–386PubMedGoogle Scholar
  58. Okada M, Nishimura H, Kawashima M et al. (1999) A new quadruple therapy for Helicobacter pylori: Influence of resistant strains on treatment outcome. Aliment Pharmacol Ther 13: 769–774PubMedCrossRefGoogle Scholar
  59. Osato MS (2000) Antimicrobial susceptibility testing for Helicobacter pylori: Sensitivity test results and their clinical relevance. Curr Pharm Des 6: 1545–1555PubMedCrossRefGoogle Scholar
  60. Osato MS, Reddy R, Reddy SG, Penland RL, Graham DY (2001). Comparison of the E-test and the NCCLS-approved agar dilution method to detect metronidazole and clarithromycin resistant Helicobacter pylori. Int J Antimicrob Agents 17: 39–44PubMedCrossRefGoogle Scholar
  61. Perri F, Festa V, Clemente R et al. (2001) Randomized study of two »rescue« therapies for Helicobacter pylori-infected patients after failure of standard triple therapies. Am J Gastroenterol 95: 58–62Google Scholar
  62. Reinert RR, Al-Lahham A, Lemperle M et al. (2002) Emergence of macrolide and penicillin resistance among invasive pneumococcal isolates in Germany. J Antimicrob Chemother 49: 61–68PubMedCrossRefGoogle Scholar
  63. Savarino V, Zentilin P, Bisso G et al. (2000) The impact of antibiotic resistance on the efficacy of three 7-day regimens against Helicobacter pylori. Aliment Pharmacol Ther 14: 893–900PubMedCrossRefGoogle Scholar
  64. Schreiber S, Nguyen TH, Stüben M, Scheid P (2000) Demostration of a pH gradient in the gastric gland of the acid-secreating Guinea Pig mucosa. Am J Gastrointest Liver Physiol 279: G597–G604Google Scholar
  65. Sharma P, Vakil N (2003) Helicobacter and reflux disease. Aliment Pharmacol Ther 17: 297–305PubMedCrossRefGoogle Scholar
  66. Sjolund M, Wreiber K, Andersson DI et al. (2003) Long-term persistence of resistant Enterococcus species after antibiotics to eradicate Helicobacter pylori. Ann Intern Med 139: 483–487PubMedGoogle Scholar
  67. Spencer CM, Faulds D (2000) Esoprazole. Drugs 60: 321–329PubMedCrossRefGoogle Scholar
  68. Stedman CA, Barclay ML (2000) Review Article: Comparison of the pharmacocinetics, acid suppression and efficacy of proton-pump inhibitors. Aliment Pharmacol Ther 14: 963–978PubMedCrossRefGoogle Scholar
  69. Stolte M (2000) Morphologie der Helicobacter pylori Gastritis. In: Malfertheiner P (Hrsg) Helicobacter pylori — Von der Grundlage zur Therapie. Thieme, Stuttgart, S 45–58Google Scholar
  70. Suerbaum S, Leying H, Klemm W, Opferkuch W (1991) Antibacterial activity of pantoprazole and omeprazole against Helicobacter pylori. Eur J Clin Microbiol Infect is 10: 92–93CrossRefGoogle Scholar
  71. Talley NJ, Stanghellini V, Heading RC et al. (1999) Functional gastroduodenal disorders. Gut 45(Suppl. 2): 1137–1142Google Scholar
  72. Talley NJ, Holtmann G, Agreus L, Jones M (2000) Gastrointestinal symptoms and subjects cluster into distinct upper and lower groupings in the community: a four nations study. Am J Gastroenterol 95: 1439–1447PubMedCrossRefGoogle Scholar
  73. Trautmann M, Riediger C, Moricke A, Vogt K, Bohr U, Glasbrenner B (1999) Combined activity of azithromycin and lansoprozole against Helicobacter pylori. Helicobacter 4: 113–120PubMedCrossRefGoogle Scholar
  74. Trevisani L, Sartori S, Galvani F et al. (1998) Evaluation of a new ultrashort triple therapy of Helicobacter pylori disease. Aliment Pharmacol Ther 12: 1269–1272PubMedCrossRefGoogle Scholar
  75. Uemura N, Okamoto S, Yamamoto S et al. (2001) Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 345: 784–789PubMedCrossRefGoogle Scholar
  76. Uemura N, Okamoto S, Yamamoto S et al. (2001) Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 345: 784–789PubMedCrossRefGoogle Scholar
  77. Vaira D, Vakil N, Rugge M et al. (2003) Effect of helicobacter eradication on development of dyspeptic and reflux disease in healthy asymptomatic subjects. Gut 52: 1543–1547PubMedCrossRefGoogle Scholar
  78. Van der Wouden EJ, Thijs JC, van Zwet AA, Sluiter WD, Kleibeuker JH (1999) The influence of in vitro Nitroimidazole resistance on the efficacy of Nitroimidazole-containing anti-Helicobacter pylori regimes: A meta-analysis. Am J Gastroenterology 94: 1751–1759CrossRefGoogle Scholar
  79. Van der Wouden EJ, Thijs JC, van Zwet AA, Kleibeuker JH (2000) Review Article: Nitroimidazole resistance in Helicobacter pylori. Aliment Pharmacol Ther 14: 7–14CrossRefGoogle Scholar
  80. Van Oijen AHAM, Verbeek AL, Jansen JBMJ, De Boer WA (2000) Review Article: Treatment of Helicabacter pylori infection with Ranitidine, Bismuth Citrate-or proton pump inhibitor-based triple therapies. Aliment Pharmacol Ther 14: 991–999PubMedCrossRefGoogle Scholar
  81. Van Zwet AA, Thijs JC, de Graaf B (1995) Explanations for high rates of eradication with the triple therapy using Metronidazole in patients harboring Metronidazole-resistent Helicobacter pylori strains. Antimicrob Agents Chemother 39: 250–252PubMedGoogle Scholar
  82. Weiss K, Laverdière M, Restrieri C (1998) Comparison of activity of 10 antibiotics against clinical strains of Helicobacter pylori by three different techniques. Can J Gastroenterol 12: 181–185PubMedGoogle Scholar
  83. Watanabe Y, Aoyama N, Shirasaka D et al. (2003) Levofloxacin based triple therapy as a second-line treatment after failure of helicobacter pylori eradication with standard triple therapy. Dig Liver Dis 35: 711–715PubMedCrossRefGoogle Scholar
  84. Welage LS, Berardi RR (2000) Evaluation of Omeprazole, Lanzoprazole, Pantoprazole and Rabeprazole in the treatment of acid-related diseases. J Am Pharm Assoc 40: 52–62Google Scholar
  85. Wong WM, Gu Q, Lam SK et al. (2003) Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection. Aliment Pharmacol Ther 17: 553–560PubMedCrossRefGoogle Scholar
  86. Zullo A, Hassan C, De F, V, Lorenzetti R et al. (2003) A third-line levofloxacin-based rescue therapy for Helicobacter pylori eradication. Dig Liver Dis 35: 232–236PubMedCrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag Heidelberg 2006

Authors and Affiliations

  • W. Opferkuch
    • 1
  • M. Kist
    • 2
  • W. F. Caspary
    • 3
  1. 1.Med. Mikrobiologie und ImmunologieRuhr-Universität BochumBochum
  2. 2.Abt. Mikrobiologie und HygieneUniversitätsklinikum FreiburgFreiburg
  3. 3.Medizinische Klinik I, Klinikum der Johann WolfgangGoethe-UniversitätFrankfurt am Main

Personalised recommendations